Canaccord analyst Sumant Kulkarni lowered the firm’s price target on KemPharm to $19 from $20 and keeps a Buy rating on the shares. The analyst said he would utilize any weakness to buy the shares as the company preps to file as early as 3Q 2023 versus 1Q 2023. He said the delay in a potential NDA refiling could be as modest as 3-4 months if one were to take a glass half-full view and said they remain well capitalized with a cash runway that he estimates extends into 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KMPH:
- Hunting for Undervalued, Overlooked Stocks? Analysts Suggest 2 Names to Buy
- KemPharm to Report Third Quarter 2022 Financial Results
- KemPharm supports Niemann-Pick Awareness Month
- KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
- KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue